-
14 selected medicines in centralized procurement will be investigated!
Time of Update: 2021-12-31
Among them, the document mentioned that in the process of monitoring the national centralized procurement of drugs, the Yunnan Provincial Medical Insurance Bureau found that some selected companies failed to supply the selected drugs in time and in accordance with the needs of medical institutions.
-
Puli Pharmaceutical's desloratadine dry suspension obtained marketing authorization in the Netherlands
Time of Update: 2021-12-31
Related symptoms of allergic rhinitis and urticaria .
The release of chemical media relieves the symptoms of allergic rhinitis and urticaria .
-
54 listed companies are expected to increase their annual performance in 2021. What is the performance of Pharmaceutical Biology?
Time of Update: 2021-12-31
The annual performance forecast disclosed by the company on October 27 shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 170 million yuan to 187 million yuan.
-
Simcere's 2 new anti-tumor drugs SIM1811-03 and paxalisib were approved for clinical use
Time of Update: 2021-12-31
They are: the self-developed anti-TNFR2 antibody SIM1811-03, It is intended to be used for the treatment of advanced solid tumors and skin T-cell lymphoma; the PI3K/mTOR pathway inhibitor paxalisib, which was introduced over US$290 million, is intended to be used for newly diagnosed and relapsed glioblastoma (GBM) .
-
Shuanglu Pharmaceutical DT678 Tablets Obtained the Notification of Drug Clinical Trial Approval
Time of Update: 2021-12-31
On December 7, Shuanglu Pharmaceutical issued an announcement stating that the company had recently received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration for DT678 tablets .
DT678 tablet is the world's first innovative drug in the field of anti-platelet aggregation drugs.
-
A large number of pharmaceutical companies announced that the product will be included in the National Medical Insurance Catalog (2021)
Time of Update: 2021-12-31
At the same time, on December 3, a large number of pharmaceutical companies issued announcements stating that their products were included in the National Medical Insurance Catalog (2021) .
-
Since the beginning of 2021, more than 200 senior executives in the pharmaceutical industry have resigned!
Time of Update: 2021-12-31
Chu Xiaojun holds a total of 960,000 shares in the company, and she promises to manage the shares held in strict accordance with the relevant regulations on the transfer of directors, supervisors, and senior executives .
-
Guangxi Province Issues a Notice of Establishing and Improving the "Dual Channel" Management Mechanism for National Medical Insurance Negotiation Drugs
Time of Update: 2021-12-31
The "Notice" stated that "dual-channel" medical institutions are encouraged to provide "Internet +" drug circulation services, standardize Internet sales services, and achieve "online ordering store pickup" or "online ordering store delivery" .
-
Against prostate cancer!
Time of Update: 2021-12-31
ArticleMedicine GuanlanOn December 6, Impair Pharmaceuticals announced that its PARP inhibitor senaparib (IMP4297) for the treatment of prostate cancer has been approved by the China National Medical Products Administration (NMPA) for a clinical trial application .
-
Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021
Time of Update: 2021-12-31
Hengrui Pharmaceuticals independently developed a category 1 innovative drug and China's first original PARP inhibitor fluzoparib successfully entered the new version of the medical insurance catalog .
-
Summary of the highlights of the pharmaceutical equipment market in 2021: the proportion of biopharmaceutical products has increased rapidly
Time of Update: 2021-12-30
Chutian Technology said in a survey report disclosed on November 29 that one of the highlights of this year's business is: the rapid increase in the proportion of products used in the field of biopharmaceuticals, which accounted for more than 40% of revenue and new orders .
-
Cooperation between pharmaceutical companies and precision diagnosis companies has become a new trend in the industry
Time of Update: 2021-12-30
According to the strategic cooperation memorandum, the two companies will jointly create an end-to-end collaborative innovation service model, covering market access, doctor-patient education, research and development of new biomarkers, and the establishment of a big data platform .
-
The traditional Chinese medicine formula granule industry has been "spilled with cold water", and the hard practice of internal strength has become a rigid requirement
Time of Update: 2021-12-30
. After the above-mentioned requirements appear, the industry believes that the current sales of Chinese medicine formula granules in the hospital may be affected .
However, some people in the industry pointed out that these requirements are only regulations for the standardized use of Chinese medicine formula granules.
-
Cinda failed to introduce ISAC drug clinical research and development, Bolt stock price plummeted 56%
Time of Update: 2021-12-30
As a new immunotherapy, the Boltbody ISAC platform consists of three main components: tumor-targeting antibodies, non-degradable linkers, and proprietary immunostimulants (TLR 7/8 agonists) used to activate the patient’s innate immune system .
-
A pharmaceutical company was fined over 30 million!
Time of Update: 2021-12-30
Under the continuous tightening of supervision, it is not uncommon for pharmaceutical companies to be punished and warned by the provincial drug regulatory bureaus for the production and sales of counterfeit and inferior drugs .
-
The seventh batch of national procurement is ready to come out, the industry: the variety of injections or "the highlight"
Time of Update: 2021-12-30
According to relevant statistics, the terminal sales of this product in China's public medical institutions will be 245 million yuan in 2020.
. For another example, lenvatinib oral dosage form and irinotecan injection have been reviewed by 5 companies, of which irinotecan injection is also a large variety with sales of over 1 billion yuan .
-
Fuhong Hanlius' PD-1 inhibitor international multi-center phase III clinical study reaches the primary endpoint of OS
Time of Update: 2021-12-30
The main purpose of this study is to study the effectiveness and safety of slulimumab combined with chemotherapy in ES-SCLC patients who have not received previous treatment .
-
Nalalong original milk powder for the elderly, to protect intestinal health 2022 Jinan Old Expo exhibitors recommended
Time of Update: 2021-12-30
Next year, we will continue to join hands with 300 domestic and foreign institutions and enterprises related to elderly care, health, service, technology and other relevant exhibitions, which will bring more quality elderly care services and products to our country .
-
The conditions for applying for a licensed pharmacist have been changed
Time of Update: 2021-12-30
In accordance with the requirements of the "Regulations", those who have obtained the corresponding academic qualifications or degrees in pharmacy and Chinese pharmacy related majors will have a corresponding increase in the number of years of work in pharmacy or Chinese pharmacy by one year .
-
New domestic hepatitis B drugs will enter medical insurance, and the tens of billions market will be reshaped!
Time of Update: 2021-12-30
Recently, the 2021 national medical insurance catalog released the results of the negotiations, Hansen Pharmaceutical Class 1 hepatitis B drug constant Mu ® (tenofovir tablets Amy) (TMF) also passed Medicare to negotiate for the treatment of chronic hepatitis B in adult patients .
